Autologous hematopoietic stem cells (HSCs) harvested as back-up prior to allogeneic hematopoietic SCT (HSCT) may potentially be useful in the treatment of graft failure or in cases with severe GVHD. Here, we studied the general policies and indications for autologous back-up harvest among the European Group for Blood and Marrow Transplantation centers in the year 2003. The outcome of patients receiving autologous back-up transfusion between 1998 and 2002 was evaluated retrospectively. The responses from 94 centers showed that 48 centers had a general policy with variable indications for autologous back-up harvest. Thirty-five patients with graft failure (25), GVHD (8) or relapse (2) retransplanted with autologous back-ups were reported. Autologous back-up transfusion was performed at a median of 35 days (patients with graft failure) or 90 days (patients with GVHD) after allogeneic HSCT. Within 100 days after autologous HSCT, 21 patients died from treatmentrelated complications (19) or relapse (2). Estimated overall survival at 1 year was 16% (95% CI 0-32%) for patients treated for graft failure and 13% (95% CI 0-37%) for GVHD patients. In conclusion, our data demonstrate that the indication for autologous back-up harvests is limited and that general storage and use cannot be recommended unless in selected prospective studies.
Introduction
Graft failure or graft rejection is a serious and potentially life-threatening complication after allogeneic hematopoietic SCT (HSCT), which occurs at an overall frequency of less than 5%. 1 Management of this complication has consisted of the infusion of hematopoietic stem cells (HSCs) from the original donor (stem cell boost) with or without immunsuppressive or cytotoxic treatment 2, 3 or of a second allogeneic HSCT using a different donor. 1 Particularly in the case of prolonged marrow aplasia, infection contributes mostly to the poor prognosis of patients with graft failure. 1, 4, 5 As a consequence, it appears to be reasonable to identify patients at risk as soon as possible and to perform an autologous transplantation using an autologous HSC back-up, especially in those patients where a second allogeneic graft is not available or significant delay in the donor availability is to be expected. 6, 7 Various case series have suggested that autologous HSCT after failed engraftment of allogeneic HSC grafts is feasible, especially in patients with good risk disease. One larger study reported that 6 out of 10 patients with acute or chronic leukemia were alive in continuous remission after autologous rescue. 8 Another possible indication to restore the original immune system by transplanting autologous HSC after allogeneic HSCT might be the occurrence of severe and possibly life-threatening GVHD. The replacement of donor-derived alloreactive T cells by host-derived T cells might abolish alloantigen-mediated GVH reactions targeting host tissue antigens. On the other hand, host-derived autologous T cells are able to target donor-derived antigenpresenting cells and in consequence might cause aggravation of GVHD, as shown in several experimental models. 9 A previous cohort study in eight patients reported six patients with autologous and two patients with syngeneic HSCT after allogeneic HSCT who had a refractory acute or chronic GVHD. In four of these patients, a resolution of GVHD manifestations could be achieved. However, all but one patient died due to GVHD (three patients), relapse (two patients), infection (one patient) or multiorgan failure (one patient). 10 The aim of this survey was to obtain an overview on the practice of the European Group for Blood and Marrow Transplantation (EBMT) centers in the collection and application of autologous HSC back-ups.
Methods
Three hundred and six EBMT centers (all EBMT centers performing allogeneic HSCT within the study period) were invited to answer a basic questionnaire about their general policy regarding storage and use of autologous HSC backups. Those centers with experience in harvest and/or use of autologous back-ups received a second questionnaire and were asked to provide detailed information about their policy for autologous HSC collection in the year 2003 and about their experience in using autologous back-ups (between January 1998 and December 2002) . Individual patient data were completed from the ProMISe database of the EBMT.
The probability of overall survival was estimated from the time of autologous back-up transplantation using Kaplan-Meier curves.
Results

General policies regarding autologous back-up harvest
The number of contacted and responding EBMT centers with the amount of allogeneic HSCT performed during the study period are listed in Table 1 . Forty-six out of 94 responding EBMT centers reported that they do not harvest autologous back-ups before allogeneic HSCT. Of the remaining 48 centers with a policy of autologous backup harvest, 29 did not perform any autologous HSC transfusion after allogeneic HSCT within the study period. Twenty-two of the 48 centers provided further information about specific indications for back-up harvest.
Most common indications for autologous back-up harvest were use of matched unrelated or mismatched unrelated donors (17 centers) and use of transplants from cord blood (8 centers) . Only a few centers had disease specific indications such as allogeneic HSCT from unrelated donors in patients with thalassemia or other inherited disorders.
From 18 centers with experience in use of autologous HSC back-ups, 16 centers reported 35 cases of autologous retransplantation, 25 patients with graft failure, 8 with severe GVHD and 2 patients with relapsed leukemia and cytotoxic therapy. Information regarding specific indications for back-up harvest prior to allogeneic HSCT in these patients was not requested.
Patients' characteristics
Details of patients with graft failure or severe GVHD with autologous HSC back-up transfusion after allogeneic HSCT are summarized in Table 2 . All 35 patients, 26 males and 9 females, underwent allogeneic HSCT between 1998 and 2003. Median age at diagnosis of their underlying disease was 27 (0-52) years and at transplantation 29 (2-54) years. Patients received allografts after standard (25) or reduced intensity (3) conditioning therapy (for 7 patients no information about conditioning regimens was available) for treatment of CML (14), ALL (8) , AML (2), non-Hodgkin's lymphoma (4), thalassemia major (4), Hodgkin's disease (1), plasma cell leukemia (1) or metachromatic leucodystrophy (1) . Allografts from BM (13), PBSCs (14) or cord blood (4) from HLA-identical sibling donors (9), HLAmatched unrelated donors (12) , mismatched unrelated donors (6) or mismatched related donors (4) were transplanted in 31 patients (no detailed information in four patients).
Indications for autologous HSC rescue Graft failure was diagnosed at a median of 28 days after allogeneic HSCT by morphological analysis of the BM, by peripheral blood cell count and/or by chimerism analysis. A differentiation between graft failure and graft rejection was not possible in most cases. Fifteen patients had evidence for active bacterial, viral and/or fungal infection at the time of graft failure. GVHD patients had grade II (one), grade III (two) or grade IV (five) acute GVHD with /kg) at a median time of 36 days (range, 17-159) after allogeneic HSCT. Only six patients (one with graft failure) received a cytotoxic conditioning therapy (fludarabine alone or in combination with CY) prior to autologous HSC infusion, one patient with GVHD in combination with antithymocyte globulin. Immunosuppressive treatment was continued after autologous HSCT in five patients with GVHD and in one patient with graft failure. G-CSF was given in 27 patients.
Patients' outcome after autologous back-up transfusion Thirteen patients died within 20 days due to infection (11) or severe bleeding complications (2) . Four of these patients died during the first week (between 0 and 4 days after backup transfusion), suggesting that advanced infection prior to back-up transfusion might have contributed to these early deaths. In the remaining 22 patients, autologous neutrophil engraftment could be observed in 16 patients. Interestingly, four patients (two treated for graft failure, one for GVHD and one for relapse) showed new onset or increased GVHD activity after autologous engraftment. Seven patients relapsed and died between 1 and 61 months after autologous HSCT. In summary, these outcomes resulted in an estimated overall survival at 1 year of 16% (95% confidence interval 0-32%) for patients treated for graft failure and of 13% (95% CI 0-37%) for patients treated for GVHD. Survival rates for both subgroups remained stable at the same level up to 4-5 years after autologous back-up transfusion (Figure 1 ).
Discussion
General policies and indications for harvesting of autologous HSC back-ups before allogeneic HSCT vary greatly among transplant centers within the EBMT. In line with previous publications, our data have shown that autologous HSCT did not overcome the dismal prognosis of patients with graft failure or severe GVHD, particularly in Severe GVHD (n =8) Figure 1 Probability of overall survival estimated by Kaplan-Meier curves for patients receiving autologous hematopoietic stem cell back-ups after allogeneic hematopoietic SCT for the treatment of graft failure (n ¼ 25, solid line) or severe GVHD (n ¼ 8, dashed line). cases with active infection at the time of transplantation. 8 Notably, three of the five patients with inherited disorders survived, suggesting that autologous back-up harvested before high-risk allogeneic HSCT might be an option in this particular patient group. Although this retrospective study is one of the largest case series with patients receiving autologous HSC backups for the treatment of graft failure or severe GVHD, it might be limited as the number of patients is small. Unfortunately, only one-third of the contacted EBMT centers, making up one-third of all unrelated transplants within the study period, responded to our survey, leaving it questionable whether our study was representative. In addition, patients with for example, myelodysplastic syndrome, severe aplastic anemia or osteomyelofibrosis who are considered to have a higher risk of graft failure were not reported within our survey.
In conclusion, taking into account the limitations mentioned above, the role of back-up harvest of autologous HSC prior to allogeneic HSCT is limited and general storage of back-ups cannot be recommended unless in selected trial settings. Future preclinical and clinical studies in this field should address the question whether cytotoxic and immunosuppressive treatments might improve the clinical outcome of patients receiving autologous HSC back-up for the treatment of graft failure or severe GVHD. Alternatively, particularly in patients with graft failure, a second allogeneic transplantation with intensification of the immunosuppressive treatment using the same or a different donor, including transplants from haploidentical donors or cord blood, might be an option. 1, 11, 12 
